Immutep Ltd has released a press release.
Phase II study for eftilagimod alpha in COVID-19 advances
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
- Recruitment of head & neck cancer patients completed for ph2
- Immutep granted US patent for eftilagimod alpha with a PD-1
- Immutep Upscales Efti Manufacturing
- Immuteps partner EOC pharma to start Ph II trial in MBC
Later from Immutep
- Immutep secures second US patent grant for eftilagimod alpha
- S&P DJI Announces March 2021 Quarterly Rebalance
- Immutep collaborates with MSD for phase 2b head & neck trial
- Immutep announces European Patent Grant for LAG525
- Immutep achieves Fast Track designation for Efti from US FDA
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep